

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8366 - SCA / BSN

SECTION 1.2

Description of the concentration

1. On 20 January 2017, the European Commission received the notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (“the EUMR”), by which SCA Group Holding BV (The Netherlands), a wholly owned subsidiary of Svenska Cellulosa Aktiebolaget SCA (“SCA”), intends to acquire within the meaning of Article 3(1)(b) of the EUMR sole control of BSN medical Luxembourg Group Holding (“BSN”, Luxembourg), a wholly owned subsidiary of Boston Luxembourg I S.à.r.l. (Luxembourg) and part of the EQT group of private equity funds based in Guernsey, the UK.
2. The business activities of the undertakings concerned are:
 - For SCA: the development, production and marketing of personal care products, tissue products and forest products;
 - For BSN: the development, manufacturing and marketing of wound care, compression therapy and orthopaedic products.